{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:15:28Z","timestamp":1792444528520,"version":"4.5.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"38","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,20]]},"DOI":"10.18632\/oncotarget.11209","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T20:34:48Z","timestamp":1470947688000},"page":"61081-61092","source":"Crossref","is-referenced-by-count":27,"title":["Novel B55\u03b1-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest"],"prefix":"10.18632","volume":"7","author":[{"given":"Geoffrey","family":"Shouse","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Loma Linda University School of Medicine, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"de Necochea-Campion","sequence":"additional","affiliation":[{"name":"Loma Linda University Cancer Center, Biospecimen Laboratory, Loma Linda University School of Medicine, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saied","family":"Mirshahidi","sequence":"additional","affiliation":[{"name":"Loma Linda University Cancer Center, Biospecimen Laboratory, Loma Linda University School of Medicine, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of California, Riverside, Riverside, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Shing","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Loma Linda University School of Medicine, Loma Linda, CA, USA"},{"name":"Loma Linda University Cancer Center, Biospecimen Laboratory, Loma Linda University School of Medicine, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Bloomfield","year":"2015","journal-title":"New Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/asheducation-2009.1.396","article-title":"Optimal induction and post-remission therapy for AML in first remission","author":"Rowe","year":"2009","journal-title":"HEMATOL"},{"key":"3","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.clinthera.2009.11.017","article-title":"Current and emerging therapies for acute myeloid leukemia","volume":"31","author":"Wierzbowska","year":"2009","journal-title":"Clin Ther"},{"key":"4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/156800912800673248","article-title":"Novel and emerging drugs for acute myeloid leukemia","volume":"12","author":"Tallman","year":"2012","journal-title":"Curr cancer drug targets"},{"key":"5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation-2005.1.143","article-title":"New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents","author":"Tallman","year":"2005","journal-title":"HEMATOL"},{"key":"6","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1179\/102453312X13336169155457","article-title":"Novel therapeutic strategies for AML in 2012","volume":"17","author":"Tallman","year":"2012","journal-title":"HEMATOL"},{"key":"7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2006-12-061283","article-title":"Constitutive phosphoinositide 3-kinase\/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients","volume":"110","author":"Dreyfus","year":"2007","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/leu.2008.395","article-title":"The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia","volume":"23","author":"Recher","year":"2009","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1074\/jbc.M709585200","article-title":"Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt","volume":"283","author":"Chiang","year":"2008","journal-title":"J Biol Chem"},{"key":"10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/leu.2011.146","article-title":"Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients","volume":"25","author":"Kornblau","year":"2011","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.molcel.2008.08.006","article-title":"Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation","volume":"31","author":"Shi","year":"2008","journal-title":"Mol Cell"},{"key":"12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Seelow","year":"2014","journal-title":"Nature methods"},{"key":"13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/msb.2009.93","article-title":"A global view of protein expression in human cells, tissues, and organs","volume":"5","author":"Ottosson","year":"2009","journal-title":"Mol Syst Biol"},{"key":"14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bcp.2012.01.022","article-title":"Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel","volume":"83","author":"Roy","year":"2012","journal-title":"Biochem Pharma"},{"key":"15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2014.141","article-title":"Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity","volume":"28","author":"Odero","year":"2014","journal-title":"Leukemia"},{"key":"16","article-title":"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours","author":"Wenham","year":"2014","journal-title":"Brit J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/pbc.25023","article-title":"A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study","volume":"61","author":"Blaney","year":"2014","journal-title":"Ped Blood Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-13-1978","article-title":"Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia","volume":"20","author":"Burger","year":"2014","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-7-1","article-title":"Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin\/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors","volume":"7","author":"de Bono","year":"2014","journal-title":"J HEMATOL Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2013.226","article-title":"Targeting the PI3K\/Akt\/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential","volume":"28","author":"Capitani","year":"2014","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.18632\/oncotarget.1236","article-title":"The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy","volume":"4","author":"Neri","year":"2013","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Heaton","year":"2011","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Marcucci","year":"2007","journal-title":"J Clin Invest"},{"key":"24","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Zhang","year":"2013","journal-title":"J Clin Invest"},{"key":"25","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jcb.24003","article-title":"Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation","volume":"113","author":"Huang","year":"2012","journal-title":"J Cell Biochem"},{"key":"26","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.bbamcr.2014.05.006","article-title":"The protein phosphatase 2A regulatory subunit B55alpha is a modulator of signaling and microRNA expression in acute myeloid leukemia cells","volume":"1843","author":"Hail","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"27","article-title":"Dual PI3K\/mTOR inhibition shows antileukemic activity in MLL rearranged acute myeloid leukemia","author":"Schneider","year":"2014","journal-title":"Leukemia"},{"key":"28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11912-012-0227-y","article-title":"PI3K and mTOR signaling pathways in cancer: new data on targeted therapies","volume":"14","author":"Bouscary","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"29","first-page":"757","article-title":"Single cell analysis of phosphoinositide 3-kinase\/Akt and ERK activation in acute myeloid leukemia by flow cytometry","volume":"91","author":"Lacombe","year":"2006","journal-title":"Haematologica"},{"key":"30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10555-008-9119-x","article-title":"Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias","volume":"27","author":"Neviani","year":"2008","journal-title":"Cancer Met Rev"},{"key":"31","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Neviani","year":"2013","journal-title":"The Lancet Oncology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.V1341073","article-title":"First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients","volume":"13","author":"Neumayer","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"33","first-page":"236","article-title":"Fingolimod. Mitsubishi Pharma\/Novartis","volume":"8","author":"Dumont","year":"2005","journal-title":"IDrugs"},{"key":"34","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","article-title":"FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia","volume":"6","author":"Group","year":"2006","journal-title":"Am J Transplantation"},{"key":"35","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0091270005279799","article-title":"FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship","volume":"45","author":"Schmouder","year":"2005","journal-title":"J Clin Pharm"},{"key":"36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1006\/bbrc.2001.4352","article-title":"FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells","volume":"281","author":"Kasahara","year":"2001","journal-title":"Biochem Biophys Res Comm"},{"key":"37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1602\/neurorx.2.4.638","article-title":"Developing therapeutics for the treatment of multiple sclerosis","volume":"2","author":"Virley","year":"2005","journal-title":"NeuroRx"},{"key":"38","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1097\/01.ju.0000064938.32318.91","article-title":"Induction of apoptosis in human bladder cancer cellsandcaused by FTY720 treatment","volume":"169","author":"Katsuoka","year":"2003","journal-title":"J Urol"},{"key":"39","first-page":"1410","article-title":"Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models","volume":"62","author":"Okuyama","year":"2002","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-05-0021","article-title":"Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma","volume":"4","author":"Fan","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"41","doi-asserted-by":"crossref","first-page":"8458","DOI":"10.1158\/1078-0432.CCR-05-0447","article-title":"FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma","volume":"11","author":"Xu","year":"2005","journal-title":"Clin Cancer Research"},{"key":"42","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"Caligiuri","year":"2013","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Odero","year":"2010","journal-title":"Blood"},{"key":"44","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2013.084731","article-title":"Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells","volume":"98","author":"Odero","year":"2013","journal-title":"Haematologica"},{"key":"45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Welch","year":"2013","journal-title":"Nature"},{"key":"46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2010.294","article-title":"PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect","volume":"25","author":"Odero","year":"2011","journal-title":"Leukemia"},{"key":"47","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-09-2544","article-title":"Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers","volume":"70","author":"Verrills","year":"2010","journal-title":"Cancer Res"},{"key":"48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Goldberg","year":"2012","journal-title":"Cancer Disc"},{"key":"49","first-page":"pl1","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Schultz","year":"2013","journal-title":"Sci Signal"},{"key":"50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Larson","year":"2008","journal-title":"Nature"},{"key":"51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/35042517","article-title":"Functional genomic analysis of C. elegans chromosome I by systematic RNA interference","volume":"408","author":"Ahringer","year":"2000","journal-title":"Nature"},{"key":"53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/MCB.00983-07","article-title":"Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A","volume":"28","author":"Liu","year":"2008","journal-title":"Mol Cell Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T20:46:16Z","timestamp":1657053976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":53,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2016,9,20]]}},"alternative-id":["11209","27531894"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11209","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]}}}